+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07668453

Evaluating Adebrelimab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Unresectable Biliary Tract Cancer as First-Line Treatment

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-06-25

30

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new combination therapy for people with biliary tract cancer that cannot be removed by surgery. This Phase 2, open-label, single-arm study focuses on the safety and effectiveness of combining an immunotherapy drug called adebrelimab with two chemotherapy drugs, gemcitabine and albumin-bound paclitaxel, as a first treatment option. The main goal is to measure how many patients experience tumor shrinkage, known as the Objective Response Rate ORR. Participants will receive adebrelimab 1200 mg intravenously on Day 1 of each 21-day cycle, followed by gemcitabine 800 mgm and albumin-bound paclitaxel 100 mgm on Days 1 and 8. This treatment is given every three weeks for 6 to 8 cycles. After these cycles, adebrelimab maintenance continues for up to 2 years, while gemcitabine and albumin-bound paclitaxel are given alternately each cycle. Treatment will continue until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop. During the study, participants will be closely monitored through regular assessments to track tumor response, progression-free survival, overall survival, quality of life, and any side effects. Safety is followed from consent until 90 days after the last dose. The study plans to enroll 30 people and will last until the end of 2027, with key outcomes assessed over 24 to 36 months.

CONDITIONS

Brief Title

An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies

Research Team

Y

Yongxiang Xia, Doctor

Y

Yongxiang Xia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here